Ichor holds multiple patents that protect the innovative technology embodied in its TriGrid® Delivery System

The multidisciplinary research program undertaken by Ichor’s team of scientists and engineers has led to the development of innovative solutions for nucleic acid-based drug delivery devices and procedures able to support every phase of development.  In the broad field of electroporation-mediated drug delivery, Ichor has established freedom to operate and has achieved a strong intellectual property position in administration of nucleic acids, DNA vaccines, electroporation methods and electroporation device configurations.